Vascepa FDA Approval History

FDA Approved: Yes (First approved July 26, 2012)
Brand name: Vascepa
Generic name: icosapent ethyl
Dosage form: Capsules
Company: Amarin Corporation plc
Treatment for: Hypertriglyceridemia, Cardiovascular Risk Reduction

Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and as an adjunct to statin therapy to reduce the risk of of cardiovascular events.

Development Timeline for Vascepa

Date	Article
Dec 13, 2019	FDA Approves Vascepa (icosapent ethyl) to Reduce Cardiovascular Risk
Jul 27, 2012	Amarin Announces FDA Approval of Vascepa (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer